Table 1.
Study characteristics of the included studies.
| First author (year) | Location | Continent | Study design | Anti-TNF-α agents | Sample size | Male (%) | Mean age (SD) | Remission (%) a | Follow-up (years) b | Quality score c |
|---|---|---|---|---|---|---|---|---|---|---|
| Al Rashidi et al. (2013) | Saudi Arabia | Asia | Retrospective study | IFX | 19 | 18 (94.7) | 25.6 (7.8) | 9 (47.4) | 3.67 | 7 |
| Bawazeer et al. (2010) | Saudi Arabia | Asia | Retrospective study | ADA | 11 | 11 (100.0) | 28.4 (5.6) | 10 (90.9) | 0.9 | 4 |
| Bejerano et al. (2013) | Spain | Europe | Retrospective study | IFX, ADA | 63 | 36 (57.1) | 38.9 (9.0) | 2 | 5 | |
| Calvo-Río et al. (2013) | Spain | Europe | Retrospective study | IFX, ADA | 108 | 59 (54.6) | 38.2 (10.4) | 2 | 6 | |
| Calvo-Rio et al. (2014) | Spain | Europe | Retrospective study | IFX, ADA | 124 | 68 (54.8) | 38.6 (10.4) | 84 (67.7) | 1 | 8 |
| Cantini et al. (2012) | Italy | Europe | Prospective study | IFX | 50 | 20 (40.0) | 37.5 (12.3) | 31 (62.0) | 2 | 8 |
| Yalcindag and Kose (2019) | Turkey | Asia | Retrospective study | IFX | 20 | 13(65.0) | 27.9(4.2) | 16 (80.0) | 1.73 | 4 |
| Domínguez Casas et al. (2017) | Spain | Europe | Retrospective study | IFX | 100 | 54 (54.0) | 40.7 (10.1) | 1 | 4 | |
| El Garf et al. (2018) | Egypt | Africa | Prospective study | IFX | 20 | 17 (85.0) | 31.8 (9.1) | 14 (70.0) | 1.17 | 6 |
| Fabiani et al. (2017) | Italy | Europe | Retrospective study | ADA | 40 | 22 (55.0) | 41.9 (12.0) | 21 (95.5) | 1 | 8 |
| Hamuryudan et al. (2013) | Turkey | Asia | Retrospective study | IFX | 43 | 33 (76.7) | 31.0 (8.4) | 11 (34.4) | 2.42 | 5 |
| Interlandi et al. (2014) | Italy | Europe | Retrospective study | ADA | 12 | 11 (91.7) | 24.3 (8.6) | 11 (91.7) | 1.75 | 7 |
| Katsuyama et al. (2019) | Japan | Asia | Retrospective study | IFX | 11 | 8 (72.7) | 45.1 (8.6) | 2 | 7 | |
| Keino et al. (2011) | Japan | Asia | Retrospective study | IFX | 14 | 12 (85.7) | 38.0 | 8 (57.1) | 1.58 | 7 |
| Martín-Varillas et al. (2018) | Spain | Europe | Retrospective study | ADA | 74 | 39 (52.7) | 38.7 (11.3) | 65 (87.8) | 2.89 | 8 |
| Mesquida et al. (2013) | Spain | Europe | Retrospective study | IFX, ADA | 32 | 16 (50.0) | 39.0 (11.9) | 28 (87.5) | 6.44 | 6 |
| Okada et al. (2012) | Japan | Asia | Prospective study | IFX | 63 | 56 (88.9) | 37.4 (11.6) | 21 (43.8) | 1 | 5 |
| Takeuchi et al. (2014) | Japan | Asia | Retrospective study | IFX | 164 | 133 (81.1) | 40.0 (11.7) | 67 (40.9) | 2.74 | 8 |
NA, not available; ADA, adalimumab; IFX, infliximab.
a
The number of patients with ocular remission (the proportion of patients with ocular remission).
b
The mean duration of follow-up.
c
Study quality was assessed using the Newcastle-Ottawa Scale. The score indicates the percentage of items met by each included study.